Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: Orforglipron in Pediatric Obesity
NCT06672549Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised trial of orforglipron in obesity, sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants Allocated to Each ISA at 72 weeks. Started Nov 2024; status: recruiting.
02
Drugs
orforglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06672549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672549.